{"filing":{"accession_number":"0001193125-26-350445","cik":"0001699382","ticker":"PMVP","company_name":"PMV Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-08-14","report_date":"2026-08-14","primary_document":"pmvp-20260814.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1699382/000119312526350445/pmvp-20260814.htm"},"events":[{"id":27743,"run_id":25317,"accession_number":"0001193125-26-350445","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"PMV Pharmaceuticals issued a press release on August 14, 2026, announcing its financial results for the second quarter ended June 30, 2026. The disclosure includes condensed consolidated balance sheets, statements of operations and comprehensive loss, and detailed financial metrics (net loss of $18.1 million for Q2 2026, R\u0026D expenses of $14.7 million, cash position of $79.4 million). This is a standard quarterly earnings release with full financial statements attached as Exhibit 99.1, typical of Item 2.02 disclosures.","company_name":"PMV Pharmaceuticals, Inc.","ticker":"PMVP","filing_date":"2026-08-14","form":"8-K","submitted_at":null,"items":[{"id":29407,"accession_number":"0001193125-26-350445","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"PMV Pharmaceuticals issued a press release on August 14, 2026, announcing its financial results for the second quarter ended June 30, 2026. The disclosure includes condensed consolidated balance sheets, statements of operations and comprehensive loss, and detailed financial metrics (net loss of $18.1 million for Q2 2026, R\u0026D expenses of $14.7 million, cash position of $79.4 million). This is a standard quarterly earnings release with full financial statements attached as Exhibit 99.1, typical of Item 2.02 disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T12:01:59.045080+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29407,"accession_number":"0001193125-26-350445","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"PMV Pharmaceuticals issued a press release on August 14, 2026, announcing its financial results for the second quarter ended June 30, 2026. The disclosure includes condensed consolidated balance sheets, statements of operations and comprehensive loss, and detailed financial metrics (net loss of $18.1 million for Q2 2026, R\u0026D expenses of $14.7 million, cash position of $79.4 million). This is a standard quarterly earnings release with full financial statements attached as Exhibit 99.1, typical of Item 2.02 disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T12:01:59.045080+00:00","company_name":"PMV Pharmaceuticals, Inc.","ticker":"PMVP","filing_date":"2026-08-14"}]}